Efficacy, Hematologic Effects and Dose of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts
Talpaz M et al. Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 109/L): A comparison to patients with normal or high starting platelet counts. Proc ASH 2012;Abstract 176.
Dr Talpaz is Alexander J Trotman Professor of Leukemia Research, Associate Director of Translational Research at UM Comprehensive Cancer Center, Associate Chief of the Division of Hematology/Oncology and Director of Hematologic Malignancies at the University of Michigan Medical Center in Ann Arbor, Michigan.
|